Semantic Scholar uses AI to extract papers important to this topic.
Idarucizumab is the only anticoagulant reversal agent for dabigatran. Because of its high cost and limited data regarding… Expand Pradaxa (dabigatran) is a direct thrombin inhibitor approved for prevention of stroke and systemic embolism in patients with non… Expand Novel oral anticoagulants are effective and safe alternatives to vitamin-K antagonists for anticoagulation therapy. However… Expand For decades, the basis for anticoagulation therapy has been the inhibition of enzymes at various levels of the coagulation… Expand Purpose:To critically appraise the evidence on dabigatran etexilate, Pradaxa, as an alternative to warfarin for stroke prevention… Expand Dabigatran etexilate, an oral direct thrombin inhibitor, was approved by the Food and Drug Administration to reduce the risk of… Expand The invention relates to a method for preparing a pradaxa intermediate. The method is a chemical synthetic method, a synthesis… Expand Study Design. The authors present a case report of a 72-year-old man who presented with back pain and lower extremity weakness… Expand PurposeOral direct factor Xa inhibitors and oral direct thrombin inhibitors are new oral anticoagulants (NOACs) for stroke… Expand Summary: Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors… Expand